March 14 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.02.AS OF DECEMBER 31, 2018, HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $16.6 MILLION.
Full Article
Jan 23 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON ANNOUNCES PRICING OF $7 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 10.0 MILLION COMMON SHARES PRICED AT $0.70PER SHARE.
Full Article
Jan 22 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.BELLEROPHON THERAPEUTICS INC - BELLEROPHON INTENDS TO USE NET PROCEEDS FROM THIS OFFERING TO FUND WORKING CAPITAL.
Full Article
May 10 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.BELLEROPHON THERAPEUTICS Q1 BASIC EARNINGS PER SHARE $0.07 .BELLEROPHON THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.04.
Full Article
May 8 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.BELLEROPHON THERAPEUTICS - PHASE 2B STUDY TO BE A DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL IN ABOUT 90 PH-COPD PATIENTS.BELLEROPHON THERAPEUTICS - PRIMARY END POINT OF STUDY WILL BE SIX-MINUTE WALKING DISTANCE, STUDY TO ALSO ASSESS MULTIPLE SECONDARY ENDPOINTS.
Full Article
Nov 7 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon provides business update and reports third quarter 2017 financial results.Q3 loss per share $0.22.Says phase 2a study for inopulse met its primary endpoint.
Full Article
Oct 24 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing.Bellerophon Therapeutics Inc - the selling stockholders will receive all of the proceeds from any sales of the shares offered.
Full Article
Sept 27 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon announces $23 million private placement.Bellerophon Therapeutics Inc - financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners.Bellerophon Therapeutics Inc - will sell about 19.4 million shares of stock, warrants to purchase about 19.4 million shares of stock for about $23.4 million.
Full Article
Sept 5 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon announces positive top line Phase 2 data of INOpulse for treatment of Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease.Bellerophon Therapeutics Inc - acute results showed a statistically significant increase in blood vessel volume on INO compared to baseline.Bellerophon Therapeutics Inc - study therapy was well tolerated with no related safety concerns.Bellerophon Therapeutics Inc - is currently conducting a Phase 3 trial for INOpulse for treatment of Pulmonary Arterial Hypertension.Bellerophon Therapeutics Inc - top-line data for Phase 3 trial of INOpulse expected in 2018.
Full Article
Aug 7 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.12.Bellerophon Therapeutics - Anticipate reporting top line results for inovation-1 phase 3 trial in PAH in 2018.
Full Article
Earnings vs. 
Estimates